Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) is projected to release its earnings data after the market closes on Monday, February 10th. Analysts expect Vertex Pharmaceuticals to post earnings of $3.99 per share and revenue of $2.78 billion for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.
Shares of NASDAQ:VRTX opened at $469.32 on Friday. Vertex Pharmaceuticals has a 52-week low of $377.85 and a 52-week high of $519.88. The stock has a market capitalization of $120.86 billion, a price-to-earnings ratio of -235.84, a PEG ratio of 2.39 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The stock's 50-day simple moving average is $435.84 and its two-hundred day simple moving average is $462.87.
Several equities research analysts have recently commented on VRTX shares. UBS Group upped their price objective on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Morgan Stanley lifted their target price on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 5th. Cantor Fitzgerald reissued an "overweight" rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. HC Wainwright upped their price target on Vertex Pharmaceuticals from $535.00 to $550.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $502.58.
View Our Latest Report on VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.